Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.
about
Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trialExamination of genetic variants involved in generation and biodisposition of kinins in patients with angioedemaA comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirementsFocus on Extracellular Vesicles: Development of Extracellular Vesicle-Based Therapeutic SystemsAdvances and Challenges of Liposome Assisted Drug DeliveryClinical development methodology for infusion-related reactions with monoclonal antibodiesDelivery of drugs bound to erythrocytes: new avenues for an old intravascular carrierImmunosuppressive and anti-inflammatory properties of engineered nanomaterialsUltrasound contrast agents.Safety of Nanoparticles in MedicineThe janus facet of nanomaterialsSupercritical carbon dioxide design strategies: from drug carriers to soft killersX-ray-computed tomography contrast agentsInteractions of nanomaterials and biological systems: Implications to personalized nanomedicineNew dual mode gadolinium nanoparticle contrast agent for magnetic resonance imagingProteomics Study on Nonallergic Hypersensitivity Induced by Compound 4880 and OvalbuminModulation of the Coagulation Cascade Using AptamersDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.In vivo demonstration of cancer molecular imaging with ultrasound radiation force and buried-ligand microbubblesRenal retention of lipid microbubbles: a potential mechanism for flank discomfort during ultrasound contrast administration.Effect of surface architecture on in vivo ultrasound contrast persistence of targeted size-selected microbubbles.The role of poly(ethylene glycol) brush architecture in complement activation on targeted microbubble surfacesIs low-molecular weight iron dextran really the most risky iron?--Unconvincing data from an unconvincing study.Influence of Study Design Variables on Clinical Pathology Data.Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles.Cardiopulmonary hemodynamic responses to the small injection of hemoglobin vesicles (artificial oxygen carriers) in miniature pigs.Novel designed polyoxyethylene nonionic surfactant with improved safety and efficiency for anticancer drug delivery.Nanoparticles and the immune systemEvaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment.Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood modelFuture trends and emerging issues for nanodelivery systems in oral and oropharyngeal cancerNanoparticles for imaging, sensing, and therapeutic intervention.Physicochemical signatures of nanoparticle-dependent complement activation.Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces.Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management.Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery.Histamine release associated with intravenous delivery of a fluorocarbon-based sevoflurane emulsion in caninesPreparation, physical characterization and pharmacokinetic study of paclitaxel nanocrystals.Synergy between surface and core entrapped metals in a mixed manganese-gadolinium nanocolloid affords safer MR imaging of sparse biomarkers.
P2860
Q21245483-104A151F-C7EA-42E3-A886-C77749460501Q23915359-EAE15FC0-937F-4F7E-A293-16E84F8D5F26Q26744352-45B1277A-F180-483D-AC94-4125685D6EB7Q26767267-4D160FE4-FF0F-4627-B74B-552BB9295C4BQ26773160-8BE7C00C-AA23-4301-B6DC-85D4DE611B92Q26798184-064803E8-71E1-4E8B-B623-F6C7AC3F1828Q26801300-80C1C959-8369-43B2-953A-0C45B41A94FDQ27005267-B73B4506-1FFF-4715-B704-89003AC33BB1Q28077669-02AEAA78-9DAD-4BB7-8BF0-5C7639EC1F4EQ28083076-7CA2F51F-8EF7-44E9-8A62-6FFD03EA670DQ28083583-E946F90D-829E-4EFE-BC84-47FC7A66E209Q28085090-3D70C851-6E62-4EED-8D98-3259785A26A0Q28280706-897F5A90-0409-401D-B051-310B1B10D4E1Q28391849-989E2B74-AFB1-4D33-BEC4-85CC527FA10CQ28471645-B67C0891-083B-41A3-B9A8-31B561C0B0DDQ28553017-69813D26-9885-4043-A9E6-EF071FEE7760Q28816936-0B8873C6-D558-4AE9-A8DA-02B83724918EQ30275257-8E175897-2069-47BF-BEC0-06AFAE9F22A1Q30366990-4D4E3314-AC58-4E45-A460-23F63D8BD65AQ30407437-705F5C8A-7428-4A8D-8E0A-EF14313A6699Q30424128-C29EB96B-4010-4666-A973-2005EDC5EA7AQ30457849-BBCCBDE0-25B3-4370-A549-3EABCA0E310AQ30464013-B93123AC-7A1C-4F69-8925-68C42B52F3B4Q31045009-F2762CC1-7702-4316-A68A-63A8DB5AE4E8Q31160507-4EF7EB7C-FB62-4112-B35D-4F60DEE53D78Q33375795-CF07BA93-50C4-4930-98C5-2F36774C922CQ33401356-76FA4374-3905-4831-8CE1-13DD35EE822CQ33568580-6591BF6B-FDB5-46FF-8997-2564C88AA01AQ33634320-8C2F98B1-AD6D-4252-BCCE-9E66A540E924Q33730481-4B8C82DC-5ABD-4912-83A0-8EC36D81C48EQ33739773-3845DF69-6E06-4EFB-951A-A3DD067A13C1Q33881254-DE46F722-370D-4C37-BA61-85A0B736479CQ34010233-97C65FB3-5F81-40D3-8220-5085E82E33D0Q34218533-D5228AA6-4CA5-4EC6-A794-322BBF4A7FE5Q34452451-41DCD2F8-5069-4DB5-9111-AC38EA5D39EBQ34463623-7C8F906F-8BAD-4D8F-9B50-6E89D7A2F97BQ34698633-5030D6FF-363B-4BD3-98EC-73D0DDE77C73Q35007943-1789CF11-C66A-4431-BB2C-A9DE98740806Q35231632-39C0A91E-5300-4196-A74E-381988E7C80AQ35317271-7DA4E8DC-3ABD-4112-BB29-74D1140F4E46
P2860
Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Complement activation-related ...... induced acute immune toxicity.
@ast
Complement activation-related ...... induced acute immune toxicity.
@en
type
label
Complement activation-related ...... induced acute immune toxicity.
@ast
Complement activation-related ...... induced acute immune toxicity.
@en
prefLabel
Complement activation-related ...... induced acute immune toxicity.
@ast
Complement activation-related ...... induced acute immune toxicity.
@en
P1433
P1476
Complement activation-related ...... induced acute immune toxicity.
@en
P2093
Janos Szebeni
P304
P356
10.1016/J.TOX.2005.07.023
P407
P577
2005-09-02T00:00:00Z